Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.~2. Healthy, as assessed from medical history and physical examination by a study physician,~3. Written informed consent obtained from parents or legal representatives who have been properly informed about the study and are able to comply with planned study procedures.~Exclusion Criteria:~1. Vaccinated with any poliovirus vaccine prior to inclusion,~2. A household contact with OPV vaccination history in the past 4 weeks,~3. HIV infection or pharmacologic immunosuppression,~4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),~5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and intradermal injections,~6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be a contraindication for vaccination,~7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion of the investigator(s).

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 7 Weeks
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): 3 doses IPV IM at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
- Group B (Type: EXPERIMENTAL): 2 doses IPV IM at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
- Group C (Type: EXPERIMENTAL): 3 doses f-IPV ID at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
- Group D (Type: EXPERIMENTAL): 2 doses f-IPV ID at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).